Low-risk delisting strategy in highly sensitized patients without donor offers included in exchange donation programs. One single-center experience
Autores de IDIVAL
Unidades
Abstract
Donor exchange programs were designed to allocate organs for highly sensitized (HS) patients. The allocation algorithm differs slightly among countries and includes different strategies to improve access to transplants in HS patients. However, many HS patients with a calculated panel reactive of antibodies (cPRA) of 100 % remain on the waiting list for a long time. Some allocation algorithms assume immunological risk, including Imlifidase treatment, to increase the chance of transplantation in very HS patients. Here, we describe our unicenter experience of low-risk delisting strategy in 15 HS patients included in the Spanish donor exchange program without donor offers. After delisting, 7 out of 15 HS patients reduced the cPRA below 99.95 % and impacted the reduction of time on the waiting list (p = 0.01), where 5 out of 7 achieved transplantation. Within those HS that remained above 99.95 %, 1 out of 8 was transplanted. All the HS were transplanted with delisted DSA, and only one with DSA level rebounded early after transplantation. All HS transplanted after delisting maintain graft function. The transplant immunology laboratories are challenged to search intermediate risk assessment methods for delisting high HS patients.
Datos de la publicación
- ISSN/ISSNe:
- 0198-8859, 1879-1166
- Tipo:
- Article
- Páginas:
- 110806-110806
- PubMed:
- 38664156
HUMAN IMMUNOLOGY ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- Kidney transplantation; Highly sensitized patients; Donor-specific antibodies; Kidney-paired donation exchange programs; Delisting
Campos de Estudio
Financiación
Proyectos asociados
Prevalencia de la esteatohepatitis no alcohólica post-trasplante de órgano sólido. Implicación de la respuesta inmunitaria innata y adaptativa
Investigador Principal: Marcos López Hoyos
PI19/01509 . INSTITUTO DE SALUD CARLOS III. . 2020
Cambios postrasplante en las células T foliculares helper analizados mediante una valoración integral de los factores de riesgo de desarrollar anticuerpos específicos de donante “de novo”
Investigador Principal: Emilio Rodrigo Calabia
PI20/01710 . INSTITUTO DE SALUD CARLOS III. . 2021
Inflamación e inmunopatología de órganos y sistemas
Investigador Principal: Emilio Rodrigo Calabia
RD21/0005/0010 . INSTITUTO DE SALUD CARLOS III. . 2022